Last €17.18 EUR
Change Today +0.035 / 0.20%
Volume 0.0
ER4 On Other Exchanges
Symbol
Exchange
New York
As of 2:08 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

emergent biosolutions inc (ER4) Snapshot

Open
€17.17
Previous Close
€17.14
Day High
€17.18
Day Low
€16.93
52 Week High
08/20/14 - €23.00
52 Week Low
10/9/13 - €12.99
Market Cap
643.7M
Average Volume 10 Days
359.0
EPS TTM
--
Shares Outstanding
37.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EMERGENT BIOSOLUTIONS INC (ER4)

emergent biosolutions inc (ER4) Related Businessweek News

No Related Businessweek News Found

emergent biosolutions inc (ER4) Details

Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body’s immune system. The company’s biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent’s commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, which was founded in 1998, is based in Rockville, Maryland.

1,353 Employees
Last Reported Date: 03/10/14
Founded in 1998

emergent biosolutions inc (ER4) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.0M
Founder, Executive Chairman and Chairman of S...
Total Annual Compensation: $726.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $694.2K
Executive Vice President and President of Bio...
Total Annual Compensation: $474.8K
Executive Vice President and President of Bio...
Total Annual Compensation: $138.9K
Compensation as of Fiscal Year 2013.

emergent biosolutions inc (ER4) Key Developments

Emergent BioSolutions Inc. Signs Contract with the National Institute of Allergy and Infectious Diseases to Develop Dry Formulation of NuThrax

Emergent BioSolutions Inc. announced that it has signed a contract with the National Institute of Allergy and Infectious Diseases to develop a dry formulation of NuThrax, also known as AV7909, the company's next generation anthrax vaccine candidate. This five-year contract, valued at up to $29 million, provides funding for manufacturing and non-clinical activities through the preparation of an Investigational New Drug application to the U.S. Food and Drug Administration. The dry formulation of NuThrax is intended to increase stability of the vaccine candidate at ambient and higher temperatures, with the objective of eliminating the need for cold chain during shipping and storage. NuThrax is comprised of BioThrax in combination with the immunostimulatory oligodeoxynucleotide compound CPG 7909. The company is currently conducting a randomized, parallel-group, active-controlled, double-blind Phase 2 study designed to evaluate the safety and immunogenicity of NuThrax for post-exposure prophylaxis of anthrax infection using two- and three-dose immunization schedules and two dose levels. This development contract HHSN272201400038C will be administered through NIAID, part of the National Institutes of Health of the U.S. Department of Health and Human Services.

Emergent BioSolutions, Inc. and Morphosys AG Announce Agreement for Joint Development and Commercialization of Emergent's Preclinical Bi-Specific Antibody, ES414, Targeting Prostate Cancer

Emergent BioSolutions Inc.and MorphoSys AG announced an agreement for the joint development and commercialization of Emergent's preclinical bi-specific antibody, ES414, targeting prostate cancer. Under the terms of the agreement, Emergent will receive an upfront payment of USD 20 million and milestone payments of up to USD 163 million. These milestone payments are linked to specific events, including successful development of ES414 in several indications and securing approval in certain territories. Emergent and MorphoSys will jointly develop ES414, with MorphoSys bearing 64% and Emergent 36% of the total costs. Emergent will retain commercialization rights in the U.S. and Canada, with a tiered royalty obligation to MorphoSys, from mid-single digit up to 20%. MorphoSys will gain worldwide commercialization rights excluding the U.S. and Canada, with a low single digit royalty obligation to Emergent. Emergent will manufacture and supply clinical material from its manufacturing facilities in Baltimore, Maryland. Additional financial details were not disclosed.

Emergent BioSolutions Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Earnings Guidance for the Third Quarter and Second Half of 2014; Revises Earnings Guidance for the Full Year of 2014

Emergent BioSolutions Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. The company reported total revenue for second quarter 2014 of $110.3 million as compared to $82.4 million in 2013. Adjusted net income for second quarter 2014 was $9.4 million as compared to adjusted net income of $11.4 million in 2013. On a GAAP basis, the company reported second quarter 2014 net income of $5.0 million, or $0.13 per share, as compared to $10.5 million, or $0.29 per share, in 2013. Income from operations was $7.862 million against $14.712 million a year ago. Income before provision for income taxes was $7.494 million against $14.737 million a year ago. Net income attributable to Emergent BioSolutions Inc. was $5.029 million against $10.484 million a year ago. This favorable performance in revenue is a result of having the former Cangene operations consolidated with the company for the full quarter following the acquisition in February. Total revenues for the first six months of 2014 were $164.2 million as compared to $125.5 million in 2013. The adjusted net loss for the first six months of 2014 was $5.4 million as compared to adjusted net income of $4.7 million in 2013. On a GAAP basis, the company reported first half 2014 net loss of $15.2 million, or $0.41 per share, as compared to net income of $2.4 million, or $0.07 per share, in 2013. Loss from operations was $17.596 million against income $1.362 million a year ago. Loss before provision for (benefit from) income taxes was $20.947 million against income $1.416 million a year ago. Net loss attributable to Emergent BioSolutions Inc. was $15.207 million against income $2.422 million a year ago. Net cash used in operating activities was $18.426 million against net cash provided by operating activities of $28.202 million a year ago. Purchases of property, plant and equipment was $9.400 million $14.123 million a year ago. The company anticipates third quarter 2014 total revenue of $110 to $125 million. The favorable impact of this change in sales mix, along with anticipated increased international sales of its Biodefense products, should boost its profit contribution in the second half of the year and generate net income in line with its guidance of between $30 million and $40 million on a GAAP basis. As well as the GAAP guidance, they are maintaining the adjusted net income guidance of between $40 million and $50 million that they provided last quarter. The company is increasing its full year 2014 total revenue forecast to $425 to $450 million from $415 to $445 million. This increased range primarily reflects stronger-than-anticipated revenue associated with the Biodefense products acquired from Cangene. The company reaffirmed its net income guidance for the year with a forecast of adjusted net income of between $40 million to $50 million and GAAP net income of between $30 million to $40 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ER4:GR €17.18 EUR +0.035

ER4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $22.18 USD -0.71
Bavarian Nordic A/S kr113.00 DKK +0.50
Depomed Inc $14.72 USD -0.24
Flamel Technologies SA $14.77 USD +0.305
Skyepharma PLC 310.25 GBp +1.75
View Industry Companies
 

Industry Analysis

ER4

Industry Average

Valuation ER4 Industry Range
Price/Earnings 60.0x
Price/Sales 2.3x
Price/Book 1.7x
Price/Cash Flow 60.5x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EMERGENT BIOSOLUTIONS INC, please visit www.emergentbiosolutions.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.